AI
REGN icon

AXS Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

AXS Investments’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,232
Closed -$1.29M – 245
2024
Q2 		$1.29M Buy
+1,232
New +$1.19M 0.36% 106

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

AXS Investments's REGN Position: Q3 2024 in Review

AXS Investments sold out of Regeneron Pharmaceuticals (REGN) in Q3 2024, closing a stake of 1,232 shares — an estimated $1.29M sold.

AXS Investments first reported a position in REGN in Q2 2024 and held it in 1 quarter. The position peaked at $1.29M in Q2 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

  • AXS Investments reported no remaining Regeneron Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • AXS Investments sold 1,232 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $1.29M.
  • AXS Investments first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • AXS Investments's Regeneron Pharmaceuticals position peaked at $1.29M in Q2 2024.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on AXS Investments's 13F filing for Q3 2024, filed 13 Nov 2024.